PRESENTATION
SMC Laboratories is highly regarded worldwide as a consulting CRO that designs studies in line with the demands of pharmaceutical companies and research institutions.
In particular, in the MASH/NASH field, SMC is a highly regarded CRO, because of our unique STAM™ mice.
The results achieved with our STAM™ have been introduced in academic publications as well as scientific conferences.
Presentations
2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
No.27
AASLD 2014,
“L-carnitine prevents progression of non-alcoholic steatohepatitis in a mouse model with upregulation of mitochondrial pathway“ Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
No.26
AASLD 2014,
“MN-001 (tipelukast), a novel, orally bioavailable drug, reduces fibrosis and inflammation and down-regulates TIMP-1, collagen Type 1 and LOXL2 mRNA overexpression in an advanced NASH (nonalcoholic steatohepatitis) model“ MediciNova, Inc.
No.25
ICLAF 2014,
“MN-001 (tipelukast), a nonselective phosphodiesterase, 5-lipoxygenase, leukotriene, phospholipase C and thromboxane A2 inhibitor, demonstrates anti-fibrotic effects in the bleomycin-induced idiopathic pulmonary fibrosis mouse model“ MediciNova, Inc.
No.24
ADA 2014,
“Liraglutide prevents steatohepatitis, liver fibrosis, and accompanying carcinogenesis in a diabetes and nonalcoholic steatohepatitis mouse model treated with STZ-HFD“ Saga University
No.23
ATS 2014,
“Solithromycin Reduces Inflammation In Mice Caused By Bleomycin-Induced Lung Injury“ Cempra, Inc.
No.21
AACR 2014,
“Clinicopathological characterization of non-alcoholic Steatohepatitis (NASH)-derived Hepatocellular carcinoma (HCC) as a patient stratification model in mice)” The Jikei University School of Medicine
No.20
Keystone Symposia 2014,
“The NADPH Oxidase (NOX) Inhibitor GKT137831 Alleviates Liver Inflammation and Fibrosis in a Mouse Model of Non-Alcoholic Steatohepatitis (NASH)” Genkyotex S.A.